IBDEI17D ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,19541,2)
 ;;=^5007396
 ;;^UTILITY(U,$J,358.3,19542,0)
 ;;=I69.821^^67^877^26
 ;;^UTILITY(U,$J,358.3,19542,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19542,1,3,0)
 ;;=3^Dysphasia following other cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,19542,1,4,0)
 ;;=4^I69.821
 ;;^UTILITY(U,$J,358.3,19542,2)
 ;;=^5007523
 ;;^UTILITY(U,$J,358.3,19543,0)
 ;;=I69.221^^67^877^25
 ;;^UTILITY(U,$J,358.3,19543,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19543,1,3,0)
 ;;=3^Dysphasia following oth nontraumatic intracranial hemorrhage
 ;;^UTILITY(U,$J,358.3,19543,1,4,0)
 ;;=4^I69.221
 ;;^UTILITY(U,$J,358.3,19543,2)
 ;;=^5007460
 ;;^UTILITY(U,$J,358.3,19544,0)
 ;;=I69.392^^67^877^29
 ;;^UTILITY(U,$J,358.3,19544,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19544,1,3,0)
 ;;=3^Facial weakness following cerebral infarction
 ;;^UTILITY(U,$J,358.3,19544,1,4,0)
 ;;=4^I69.392
 ;;^UTILITY(U,$J,358.3,19544,2)
 ;;=^5007517
 ;;^UTILITY(U,$J,358.3,19545,0)
 ;;=I69.192^^67^877^30
 ;;^UTILITY(U,$J,358.3,19545,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19545,1,3,0)
 ;;=3^Facial weakness following nontraumatic intcrbl hemorrhage
 ;;^UTILITY(U,$J,358.3,19545,1,4,0)
 ;;=4^I69.192
 ;;^UTILITY(U,$J,358.3,19545,2)
 ;;=^5007454
 ;;^UTILITY(U,$J,358.3,19546,0)
 ;;=I69.292^^67^877^32
 ;;^UTILITY(U,$J,358.3,19546,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19546,1,3,0)
 ;;=3^Facial weakness following oth nontraumatic intcrn hemorrhage
 ;;^UTILITY(U,$J,358.3,19546,1,4,0)
 ;;=4^I69.292
 ;;^UTILITY(U,$J,358.3,19546,2)
 ;;=^5007486
 ;;^UTILITY(U,$J,358.3,19547,0)
 ;;=I69.092^^67^877^31
 ;;^UTILITY(U,$J,358.3,19547,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19547,1,3,0)
 ;;=3^Facial weakness following ntrm subarachnoid hemorrhage
 ;;^UTILITY(U,$J,358.3,19547,1,4,0)
 ;;=4^I69.092
 ;;^UTILITY(U,$J,358.3,19547,2)
 ;;=^5007422
 ;;^UTILITY(U,$J,358.3,19548,0)
 ;;=I69.892^^67^877^33
 ;;^UTILITY(U,$J,358.3,19548,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19548,1,3,0)
 ;;=3^Facial weakness following other cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,19548,1,4,0)
 ;;=4^I69.892
 ;;^UTILITY(U,$J,358.3,19548,2)
 ;;=^5007548
 ;;^UTILITY(U,$J,358.3,19549,0)
 ;;=I69.351^^67^877^36
 ;;^UTILITY(U,$J,358.3,19549,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19549,1,3,0)
 ;;=3^Hemiplga fol cerebral infrc aff right dominant side
 ;;^UTILITY(U,$J,358.3,19549,1,4,0)
 ;;=4^I69.351
 ;;^UTILITY(U,$J,358.3,19549,2)
 ;;=^5007504
 ;;^UTILITY(U,$J,358.3,19550,0)
 ;;=I69.352^^67^877^35
 ;;^UTILITY(U,$J,358.3,19550,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19550,1,3,0)
 ;;=3^Hemiplga fol cerebral infrc aff left dominant side
 ;;^UTILITY(U,$J,358.3,19550,1,4,0)
 ;;=4^I69.352
 ;;^UTILITY(U,$J,358.3,19550,2)
 ;;=^5007505
 ;;^UTILITY(U,$J,358.3,19551,0)
 ;;=I69.353^^67^877^37
 ;;^UTILITY(U,$J,358.3,19551,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19551,1,3,0)
 ;;=3^Hemiplga fol cerebral infrc aff right nondom side
 ;;^UTILITY(U,$J,358.3,19551,1,4,0)
 ;;=4^I69.353
 ;;^UTILITY(U,$J,358.3,19551,2)
 ;;=^5007506
 ;;^UTILITY(U,$J,358.3,19552,0)
 ;;=I69.354^^67^877^38
 ;;^UTILITY(U,$J,358.3,19552,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19552,1,3,0)
 ;;=3^Hemiplga fol cerebral infrc affecting left nondom side
 ;;^UTILITY(U,$J,358.3,19552,1,4,0)
 ;;=4^I69.354
 ;;^UTILITY(U,$J,358.3,19552,2)
 ;;=^5007507
 ;;^UTILITY(U,$J,358.3,19553,0)
 ;;=I69.151^^67^877^41
